期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子受体酪氨酸激酶抑制剂的研究进展 被引量：2

The development of the epidermal growth factor receptor tyrosine kinase inhibitor
下载PDF
导出
摘要 表皮生长因子受体(epidermal growth factor receptor,EGFR)在细胞的信号转导、细胞增殖和分化中发挥着重要的作用,对多种肿瘤的发生和发展也具有重要影响,抑制该受体活性可以有效抑制肿瘤的生长。以此为靶点的抗肿瘤药物的开发,在多种肿瘤治疗中取得了令人鼓舞的疗效。 Epidermal growth factor receptor plays an important role in the cell signal transduction, proliferation and differentiation and affects the development of malignant tumors. Blocking the EGFR can inhibit the growth of neoplasm effectively. The development of anti - cancer drugs that target EGFR have acquired an exciting curative effect.
作者 王章桂 孙国平
机构地区 安徽医科大学第一附属医院肿瘤科
出处 《现代肿瘤医学》 CAS 2007年第12期1857-1860,共4页 Journal of Modern Oncology
关键词 表皮生长因子受体 酪氨酸激酶抑制剂 抗肿瘤 epidermal growth factor receptor tyrosine kinase inhibitor anti- tumor
分类号 R730.231 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Niho S, Kubota K, Coto K, et al. First - line single agent treatment with gefitinib in patients with advanced non -small -cell lung cancer: A phase II study [J]. J Clin Oncol, 2006,24( 1 ) : 64 - 69.
  • 2West H L, Franklin W A, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: southwest oncology group study S0126[J]. J Clin Oncol, 2006, 24(12) :1807 - 1813.
  • 3Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase Ⅱ study of gefitinib in second - line treatment of advanced esophageal cancer patients[ J ]. Clin Oncol, 2006, 24(10) :1612 -1619.
  • 4Hotta K, Matsuo K, Ueoka H, et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non - small - cell lung cancer , Okayama Lung Cancer Study Group experience[ J ]. Annals of Oncol, 2005, 16 ( 11 ) : 1817 - 1823.
  • 5Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non - small - cell lung cancer patients treated with gefitinib [ J ]. J Clin Oncol, 2006, 24( 16 ) :2549 -2556.
  • 6Frohna P, Lu J, Eppler S, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects[ J]. J Clin Pharmacol , 2006, 46(3) :282 -290.
  • 7Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase Ⅱ study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer[ J]. J Clin Oncol, 2006, 24(12) : 1892 - 1897.
  • 8Townsley C A, Major P, Siu L L, et al. Phase Ⅱ study of erlotinib ( OSI - 774) in patients with metastatic colorectal cancer [ J ]. Br J Cancer, 2006, 94(8):1136 - 1143.
  • 9Philip P A, Mahoney M R, Allmer C, et al. Phase Ⅱ study of erlotinib in patients with advanced biliary cancer [ J]. J Clin Oncol, 2006, 24(19) :3069 - 3074.
  • 10Hainsworth J D, Sosman J A, Spigel D R, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and Erlotinib[ J]. J Clin Oncol, 2005,23(31 ) :7889 -7896.

同被引文献6

  • 1徐兵河,孙燕.埃罗替尼可提高肺癌患者生活质量[N].中国医学论坛报,2007-01-11(B4).
  • 2陆舜,李子明,虞永峰.肺癌分子靶向治疗研究进展[N].中国医学论坛报,2007-06-14(E23).
  • 3Nabhan C, Bitran JD. Erlotinib in lung cancer[J]. N Engl J Med,2005,353(16) :1739-1741.
  • 4王洁.EGFRI相关皮肤不良反应中国临床治疗指导原则[N].中国医学论坛报,2008-04-03(B5).
  • 5史艳晖,表皮生长因子受体(EGFR)在肿瘤治疗中的应用[C].中国生物工程学会第四次会员代表大会暨学术讨论会文摘要集,2005.
  • 6朱良军,刘海燕,王艳萍.特罗凯治疗晚期非小细胞肺癌28例临床观察[J].吉林医学,2010,31(22):3711-3712. 被引量：9

引证文献2

二级引证文献5

现代肿瘤医学
2007年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部